The role of metabolic surgery in the treatment of patients with type 2 diabetes mellitus


  • M.D. Tronko SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv, Ukraine
  • V.L. Orlenko SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv, Ukraine
  • S.I. Savoliuk Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • M.Yu. Krestianov Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • O.V. Dobrovynska SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv, Ukraine
  • A.Yu. Glagoleva Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • K.Yu. Ivaskiva SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv, Ukraine
  • V.M. Lysenko Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • D.S. Zavertylenko Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine



obesity, type 2 diabetes mellitus, metabolic surgery, review


The results of numerous studies have demonstrated the high effectiveness of bariatric surgery in patients with obesity and type 2 diabetes mellitus (DM). Currently, surgery is one of the most effective ways to decrease body mass, to maintain long-term weight loss and to manage type 2 DM. Particular interest has been generated by the strong positive influence of bariatric surgical interventions on the disruption of carbohydrate metabolism in patients who undergo surgery. This change leads to an improvement in the course of type 2 DM as well as its full remission. This review presents information on the mechanisms associated with glycaemic control improvement in obese patients following the bariatric surgery. This review also contains a comparative analysis of effect of various surgical interventions on DM course, the reasons for postbariatric glycaemia and predictors of the effectiveness of bariatric surgeries in terms of metabolic control in obese patients with type 2 DM. In addition, some information concerning surgical and metabolic complications of bariatric surgical intervention is provided, which needs balanced approach to the treatment method choice.


Download data is not yet available.


International Diabetes Federation. Diabetes atlas IDF. 7th ed. 2015. Available from:

Putnam J, Allshouse J, Kantor LS. U.S. per capita food supply trends: more calories, refined carbohydrates, and fats. Food Review/ National Food Review. 2002;25(3):2-15.

Church TS, Thomas DM, Tudor-Locke C, et al. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One. 2011;6(5):e19657. doi: 10.1371/journal.pone.0019657.

Loos RJ. Genetic determinants of common obesity and their value in prediction. Best Pract Res Clin Endocrinol Metab. 2012 Apr;26(2):211-26. doi: 10.1016/j.beem.2011.11.003.

Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care. 2002 Mar;25(3):608-13. doi: 10.2337/diacare.25.3.608.

Imai Y, Dobrain AD, Morris MA, Nadler JL. Islet inflammation: a unifying target for diabetes treatment? Trends Endocrinol Metab. 2013 Jul;24(7):351-60. doi: 10.1016/j.tem.2013.01.007.

Dutka RYa, Chmyr NV. Pathogenetic and clinical correlation of type 2 diabetes mellitus with metabolic syndrome and chronic coronary artery disease. Mìžnarodnij endokrinologìčnij žurnal. 2018;14(7):665-660. doi: 10.22141/2224-0721.14.7.2018.148772. (in Ukrainian).

Pitsavos C, Tampourlou M, Panagiotakos DB, et al. Association between low-grade systemic inflammation and type 2 diabetes mellitus among men and women from the ATTICA Study. Rev Diabet Stud. 2007 Summer;4(2):98-104. doi: 10.1900/RDS.2007.4.98.

Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep. 2006 Jun;6(3):177-81.

Krushinska AG, Yuzvenko TYu, Pankiv VI. Frequency of cardiovascular complications in patients with type 2 diabetes mellitus depending on antihyperglycemic therapy. Mìžnarodnij endokrinologìčnij žurnal. 2018;14(6):570-578. Doi 10.22141/2224-0721.14.6.2018.146067. (in Ukrainian).

Quiroga MAS, Mokhlesi B, Corral J, et al. Long term positive airway pressure effectiveness in obesity hypoventilation syndrome: Pickwick Study results. European Respiratory Journal. 2018;52(Suppl 62): OA5414. doi: 10.1183/13993003.congress-2018.OA5414.

Pantanetti P1, Garrapa GG, Mantero F, Boscaro M, Faloia E, Venarucci D. Adipose tissue as an endocrine organ? A review of recent data related to cardiovascular complications of endocrine dysfunctions. Clin Exp Hypertens. 2004 May;26(4):387-98.

Clement K, Vaisse C, Manning BS, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med. 1995 Aug 10;333(6):352-4. doi: 10.1056/NEJM199508103330605.

Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med. 1998 Oct 1;339(14):953-9. doi: 10.1056/NEJM199810013391403.

Kaila B, Raman M. Obesity: A review of pathogenesis and management strategies. Can J Gastroenterol. 2008 Jan;22(1):61-8. doi: 10.1155/2008/609039.

Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001 Apr;50(4):707-9. doi: 10.2337/diabetes.50.4.707.

Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001 Dec;86(12):5992. doi: 10.1210/jcem.86.12.8111.

Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology. 2005 Nov;129(5):1430-6. doi: 10.1053/j.gastro.2005.09.001.

Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003 Oct;88(10):4696-701. doi: 10.1210/jc.2003-030421.

Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20. doi: 10.1172/JCI990.

Mizuno TM, Kelley KA, Pasinetti GM, Roberts JL, Mobbs CV. Transgenic neuronal expression of proopiomelanocortin attenuates hyperphagic response to fasting and reverses metabolic impairments in leptin-deficient obese mice. Diabetes. 2003 Nov;52(11):2675-83. doi: 10.2337/diabetes.52.11.2675.

Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):29-33. doi: 10.1161/01.ATV.0000099786.99623.EF.

Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab. 2007 May;9(3):282-9. doi: 10.1111/j.1463-1326.2006.00610.x.

Longo DL, Heymsfield B, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017 Apr 13;376(15):1492. doi: 10.1056/NEJMc1701944.

American Diabetes Association. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes – 2019. Diabetes Care. 2019 Jan;42(Suppl 1):S81-S89. doi: 10.2337/dc19-S008.

Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Abingdon). 2014 Dec;42(12):698-702. doi: 10.1016/j.mpmed.2014.09.007.

Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical Guidelines for Clinical Practice for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient. Surgery for Obesity and Related Diseases. 2008;4(5 Suppl):S109-S184. doi: 10.1016/j.soard.2008.08.009.

Rey-López JP, de Rezende LF, Pastor-Valero M, Tess BH.The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. Obes Rev. 2014 Oct;15(10):781-90. doi: 10.1111/obr.12198.

Rubin JK, Hinrichs-Krapels S, Hesketh R, Martin A, Herman WH, Rubino F. Identifying Barriers to Appropriate Use of Metabolic/Bariatric Surgery for Type 2 Diabetes Treatment: Policy Lab Results. Diabetes Care. 2016 Jun;39(6):954-63. doi: 10.2337/dc15-2781.

Sinclair P, Docherty N, le Roux CW. Metabolic Effects of Bariatric Surgery. Clin Chem. 2018 Jan;64(1):72-81. doi: 10.1373/clinchem.2017.272336.

Rubio-Almanza M, Cámara-Gómez R, Hervás-Marín D, Ponce-Marco JL, Merino-Torres JF. Cardiovascular risk reduction over time in patients with diabetes or pre-diabetes undergoing bariatric surgery: data from a single-center retrospective observational study. BMC Endocr Disord. 2018 Nov 28;18(1):90. doi: 10.1186/s12902-018-0317-4.

Blüher M. Surgical Treatment of Type 2 Diabetes. Dtsch Arztebl Int. 2016 Dec 9;113(49):825-826. doi: 10.3238/arztebl.2016.0825.

Cummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia. 2018 Feb;61(2):257-264. doi: 10.1007/s00125-017-4513-y.

Cummings DE, Cohen RV. Bariatric/Metabolic Surgery to Treat Type 2 Diabetes in Patients With a BMI <35 kg/m2. Diabetes Care. 2016 Jun;39(6):924-33. doi: 10.2337/dc16-0350.

Aminian A, Brethauer SA, Kirwan JP, Kashyap SR, Burguera B, Schauer PR. How safe is metabolic/diabetes surgery? Diabetes Obes Metab. 2015 Feb;17(2):198-201. doi: 10.1111/dom.12405.

Arterburn D, Bogart A, Sherwood N et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013 Jan;23(1):93-102. doi: 10.1007/s11695-012-0802-1.

Angrisani L, Santonicola A, Iovino P, et al. Bariatric Surgery and Endoluminal Procedures: IFSO Worldwide Survey 2014. Obes Surg. 2017 Sep;27(9):2279-2289. doi: 10.1007/s11695-017-2666-x.

Nocca D, Loureiro M, Skalli EM. Five-year results of laparoscopic sleeve gastrectomy for the treatment of severe obesity. Surg Endosc. 2017 Aug;31(8):3251-3257. doi: 10.1007/s00464-016-5355-2.

Carbajo MA, Fong-Hirales A, Luque-de-León E, Molina-Lopez JF, Ortiz-de-Solórzano J. Weight loss and improvement of lipid profiles in morbidly obese patients after laparoscopic one-anastomosis gastric bypass: 2-year follow-up. Surg Endosc. 2017 Jan;31(1):416-421. doi: 10.1007/s00464-016-4990-y.

Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013 Mar;273(3):219-34. doi: 10.1111/joim.12012.

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. N Engl J Med. 2017 Feb 16;376(7):641-651. doi: 10.1056/NEJMoa1600869.

Pournaras DJ, Aasheim ET, Søvik TT, Andrews R, Mahon D, Welbourn R. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg. 2012 Jan;99(1):100-3. doi: 10.1002/bjs.7704.

Osland E, Yunus RM, Khan S, Memon B, Memon MA. Diabetes improvement and resolution following laparoscopic vertical sleeve gastrectomy (LVSG) versus laparoscopic Roux-en-Y gastric bypass (LRYGB) procedures: a systematic review of randomized controlled trials. Surg Endosc. 2017 Apr;31(4):1952-1963. doi: 10.1007/s00464-016-5202-5.

Cho JM, Kim HJ, Lo Menzo E, Park S, Szomstein S, Rosenthal RJ. Effect of sleeve gastrectomy on type 2 diabetes as an alternative treatment modality to Roux-en-Y gastric bypass: systemic review and meta-analysis. Surg Obes Relat Dis. 2015 Nov-Dec;11(6):1273-80. doi: 10.1016/j.soard.2015.03.001.

Huang X, Liu T, Zhong M, Cheng Y, Hu S, Liu S. Predictors of glycemic control after sleeve gastrectomy versus Roux-en-Y gastric bypass: A meta-analysis, meta-regression, and systematic review. Surg Obes Relat Dis. 2018 Dec;14(12):1822-1831. doi: 10.1016/j.soard.2018.08.027.

Zendel A, Abu-Ghanem Y, Dux J, Mor E, Zippel D, Goitein D. The Impact of Bariatric Surgery on Thyroid Function and Medication Use in Patients with Hypothyroidism. Obes Surg. 2017 Aug;27(8):2000-2004. doi: 10.1007/s11695-017-2616-7.

Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006 Nov;244(5):741-9. doi: 10.1097/01.sla.0000224726.61448.1b.

Hayoz C, Hermann T, Raptis DA, Brönnimann A, Peterli R, Zuber M. Comparison of metabolic outcomes in patients undergoing laparoscopic roux-en-Y gastric bypass versus sleeve gastrectomy – a systematic review and meta-analysis of randomized controlled trials. Swiss Med Wkly. 2018 Jul 5;148:w14633. doi: 10.4414/smw.2018.14626.

Rabiee A, Magruder JT, Salas-Carrillo R, et al. Hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: unraveling the role of gut hormonal and pancreatic endocrine dysfunction. J Surg Res. 2011 May 15;167(2):199-205. doi: 10.1016/j.jss.2010.09.047.

Bojsen-Møller KN. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Dan Med J. 2015 Apr;62(4):B5057.

Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013 Jan;15(1):14-33. doi: 10.1111/jch.12049.

Schiavon CA, Drager LF, Bortolotto LA, et al. The role of metabolic surgery on blood pressure control. Curr Atheroscler Rep. 2016 Aug;18(8):50. doi: 10.1007/s11883-016-0598-x.

Ahmed AR, Rickards G, Coniglio D, et al. Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure. Obes Surg. 2009 Jul;19(7):845-9. doi: 10.1007/s11695-008-9671-z.

Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013 Jul-Aug;7(4):304-83. doi: 10.1016/j.jacl.2013.04.001.

Nguyen NT, Varela E, Sabio A, Tran CL, Stamos M, Wilson SE. Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass. J Am Coll Surg. 2006 Jul;203(1):24-9. doi: 10.1016/j.jamcollsurg.2006.03.019.

Kumar R, Lieske JC, Collazo-Clavell ML, et al. Fat malabsorption and increase intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery. 2011 May;149(5):654-61. doi: 10.1016/j.surg.2010.11.015.

Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1396-402. doi: 10.1016/j.cgh.2008.08.012.

Nickel F, Tapking C, Benner L, et al. Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow up: BariScan study. Obes Surg. 2018 May;28(5):1342-1350. doi: 10.1007/s11695-017-3012-z.

Froylich D, Corcelles R, Daigle C, Boules M, Brethauer S, Schauer P. Effect of Roux-enY gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: A comparative study. Surg Obes Relat Dis. 2016 Jan;12(1):127-31. doi: 10.1016/j.soard.2015.04.004.

O'Brien R, Johnson E, Haneuse S. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study. Ann Intern Med. 2018 Sep 4;169(5):300-310. doi: 10.7326/M17-2383.



How to Cite

Tronko, M., Orlenko, V., Savoliuk, S., Krestianov, M., Dobrovynska, O., Glagoleva, A., Ivaskiva, K., Lysenko, V., & Zavertylenko, D. (2021). The role of metabolic surgery in the treatment of patients with type 2 diabetes mellitus. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 15(3), 236–245.



To practicing Endocrinologists

Most read articles by the same author(s)

1 2 3 > >>